Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022.
Détails
Télécharger: 35929427_BIB_6DDFE21CA95A.pdf (290.83 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_6DDFE21CA95A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022.
Périodique
Euro surveillance
Collaborateur⸱rice⸱s
Corona Immunitas Research Group
Contributeur⸱rice⸱s
Bochud Murielle , Bodenmann Patrick , Butty Audrey , D'Acremont Valérie , Duperrex Olivier , Dupraz Julien , Egger Malik , Estoppey Sandrine , Faivre Vincent , Felappi Andrea , Fenwick Craig , Gonseth Nusslé Semira , Jendly Emilie , Pantaleo Giuseppe , Pasquier Jérôme , Pellaton Céline , Sanchis Zozaya Javier , Schlüter Virginie , Steiner-Dubuis Amélie , Thabard Julien , Vassaux Sophie , Zuppinger Claire
ISSN
1560-7917 (Electronic)
ISSN-L
1025-496X
Statut éditorial
Publié
Date de publication
08/2022
Peer-reviewed
Oui
Volume
27
Numéro
31
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Functional immunity (defined here as serum neutralising capacity) critically contributes to conferring protection against SARS-CoV-2 infection and severe COVID-19. This cross-sectional analysis of a prospective, population-based cohort study included 1,894 randomly-selected 16 to 99-year-old participants from two Swiss cantons in March 2022. Of these, 97.6% (95% CI: 96.8-98.2%) had anti-spike IgG antibodies, and neutralising capacity was respectively observed for 94%, 92% and 88% against wild-type SARS-CoV-2, Delta and Omicron variants. Studying functional immunity to inform and monitor vaccination campaigns is crucial.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Neutralizing, Antibodies, Viral, COVID-19/immunology, COVID-19/prevention & control, COVID-19 Vaccines/administration & dosage, Cross-Sectional Studies, Humans, Immunization Programs, Immunization, Secondary, Middle Aged, Prospective Studies, SARS-CoV-2, Spike Glycoprotein, Coronavirus/immunology, Switzerland/epidemiology, Young Adult, neutralising activity, seroprevalence, variants of concern
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/08/2022 8:41
Dernière modification de la notice
23/01/2024 7:27